Loading...
Swiss Parenterals Limited — Digoxin Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #7 for Digoxin · $46.2K export value · DGFT Verified
Swiss Parenterals Limited is the #7 Indian exporter of Digoxin with $46.2K in export value and 8 verified shipments. Swiss Parenterals Limited holds a 2.1% market share in Digoxin exports across 3 countries. The company exports 18 pharmaceutical products worth $15.9M across 9 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $1.1M | 69 | 58.9% |
| SRI LANKA | $124.7K | 16 | 6.6% |
| VENEZUELA | $115.9K | 29 | 6.1% |
| CANADA | $95.5K | 8 | 5.0% |
| NIGERIA | $72.8K | 9 | 3.8% |
| ECUADOR | $66.7K | 3 | 3.5% |
| SINGAPORE | $55.0K | 60 | 2.9% |
| ALGERIA | $44.7K | 5 | 2.4% |
| KENYA | $40.8K | 17 | 2.1% |
| PHILIPPINES | $33.5K | 7 | 1.8% |
India exports Digoxin to 104 countries. The top destination is UNITED STATES (58.9%), followed by SRI LANKA and VENEZUELA.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NORTHSTAR DISTRIBUTION CENTER 8912 | UNITED STATES | $597.5K | 20 |
| SUN PHARMACEUTICAL INDUSTRIES,INC. | UNITED STATES | $259.1K | 19 |
| SUN PHARMACEUTICAL INDUSTRIES INC | UNITED STATES | $124.8K | 17 |
| JAMP PHARMA CORPORATION | CANADA | $72.7K | 4 |
| NORTHSTAR DISTRIBUTION CENTER | UNITED STATES | $57.1K | 2 |
India exported $1.6M worth of Digoxin through 886 shipments from 203 suppliers to 104 countries, serving 293 buyers globally. Swiss Parenterals Limited contributes $46.2K to this total, accounting for 2.1% of India's Digoxin exports.
Swiss Parenterals Limited's average Digoxin shipment value is $5.8K per consignment, based on 8 shipments totaling $46.2K.
Swiss Parenterals Limited ranks #7 among 203 Indian Digoxin exporters with a 2.1% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($993.4K), SUN PHARMACEUTICAL INDUSTRIES LTD ($99.5K), UNICURE REMEDIES PRIVATE LIMITED ($82.0K). Swiss Parenterals Limited processed 8 shipments to 3 destination countries.
What Swiss Parenterals Limited must comply with to export Digoxin to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | VENOR PHARMA LIMITED | $67.5K | 7 | 6 | $9.6K |
| 6 | CARITAS HEALTHCARE PRIVATE LIMITED | $66.7K | 3 | 1 | $22.2K |
| 7 | SWISS PARENTERALS LIMITED ★ | $46.2K | 8 | 3 | $5.8K |
| 8 | CIRON DRUGS AND PHARMACEUTICALS PRIVATE LIMITED | $41.9K | 11 | 7 | $3.8K |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 206 | 23.3% |
| SAHAR AIR CARGO ACC (INBOM4) | 167 | 18.8% |
| NHAVA SHEVA SEA (INNSA1) | 66 | 7.4% |
| DELHI AIR CARGO ACC (INDEL4) | 57 | 6.4% |
| Bombay Air | 56 | 6.3% |
| DELHI AIR | 47 | 5.3% |
| AHEMDABAD AIR ACC (INAMD4) | 27 | 3.0% |
| JNPT | 23 | 2.6% |
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Swiss Parenterals. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight costs and extended delivery times. Such maritime challenges can significantly impact the timely distribution of pharmaceuticals, especially to Middle Eastern markets. (pharmaceuticalcommerce.com)
Conversely, escalating US-China trade tensions have prompted the United States to diversify its import sources, potentially benefiting Indian exporters. However, recent US tariff policies, including a 25% tariff on Indian imports due to geopolitical alignments, pose a substantial challenge, potentially affecting nearly 55% of India's exports to the US. (apnews.com)
In the European Union, stringent regulatory frameworks like the Falsified Medicines Directive necessitate compliance with rigorous safety and quality standards. For companies like Swiss Parenterals, adhering to these regulations is crucial to maintain and expand their presence in EU markets.
The global pharmaceutical industry is witnessing heightened scrutiny regarding quality and compliance. Indian exporters, including Swiss Parenterals, must navigate complex regulatory environments, ensuring adherence to FDA, WHO, and EU GMP standards. The US FDA's increased inspections of Indian facilities underscore the importance of maintaining high-quality manufacturing practices to avoid potential export bans or recalls. (fact.net.in)
Swiss Parenterals' integration into Eris Lifesciences is expected to bolster its compliance infrastructure, leveraging Eris's established quality management systems to meet international regulatory requirements effectively.
Swiss Parenterals Limited exports 18 products worth $15.9M. Beyond Digoxin, top products include Ceftriaxone, Meropenem, Prednisolone, Fosfomycin, Methylprednisolone. View the complete Swiss Parenterals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Digoxin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Swiss Parenterals Limited's Digoxin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Swiss Parenterals Limited
Full Company Profile →
18 products · $15.9M total trade · 9 categories
| SUN PHARMACEUTICAL INDUSTRIESINC. | UNITED STATES | $54.5K | 3 |
| F.D.E.C.A | ECUADOR | $38.7K | 2 |
| GREAT TIMEC PHARMA COMPANY LIMITED | NIGERIA | $28.2K | 4 |
| LEBOO HEALTHCARE PRODUCTS C.A | VENEZUELA | $26.2K | 6 |
| ACTIVO INGREDINETS PTE LTD. | SINGAPORE | $25.9K | 5 |
India's Digoxin is purchased by 293 buyers worldwide. The top buyer is NORTHSTAR DISTRIBUTION CENTER 8912 (UNITED STATES), followed by SUN PHARMACEUTICAL INDUSTRIES,INC. and SUN PHARMACEUTICAL INDUSTRIES INC.
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 9 |
| NEM LABORATORIES PVT LTD |
| $38.8K |
| 12 |
| 3 |
| $3.2K |
Swiss Parenterals Limited ranks #7 among 203 Indian Digoxin exporters. Average shipment value of $5.8K compared to the market average of $8.0K. The closest competitors by value are VENOR PHARMA LIMITED and CARITAS HEALTHCARE PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 104+ countries, 293+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Swiss Parenterals Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Digoxin. For current shipment-level data, contact TransData Nexus.